8-K: Avalo Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Avalo Therapeutics announced its Q1 2025 financial results, highlighting progress in the Phase 2 LOTUS trial for AVTX-009 and a cash runway into 2027.

Summary

• Avalo Therapeutics announced its first quarter 2025 financial results and provided business updates.
• Mike Heffernan has been appointed as Chairman of the Board.
• Topline data from the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa is expected in 2026.
• The company's cash on hand was approximately $125 million as of March 31, 2025, which is expected to fund operations into 2027, with potential to extend into 2028.
• The Phase 2 LOTUS trial is a global study evaluating AVTX-009 in approximately 180 adults with hidradenitis suppurativa.
• Avalo is also evaluating AVTX-009 for additional immune-mediated diseases and plans to announce a second indication.
• Net cash used in operating activities was $9.5 million for the first quarter of 2025.
• Research and development expenses were $9.1 million for the first quarter of 2025, an increase of $7.0 million from the first quarter of 2024.
• General and administrative expenses were $5.5 million for the first quarter of 2025, an increase of $2.4 million from the first quarter of 2024.
• Net loss was $13.1 million for the first quarter of 2025, a decrease of $108.2 million from $121.3 million in the first quarter of 2024.
• Basic and diluted net loss per share was $1.25 for the first quarter of 2025, compared to $141.14 for the first quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, progress in the LOTUS trial, and decrease in net loss. However, increased R&D and G&A expenses temper the overall outlook.

Positives

• The company has a strong cash position of $125 million, expected to fund operations into 2027.
• Net loss significantly decreased from $121.3 million in Q1 2024 to $13.1 million in Q1 2025.
• Progress in the Phase 2 LOTUS trial is on track, with topline data expected in 2026.
• The company is exploring a second indication for AVTX-009.

Negatives

• Research and development expenses increased by $7.0 million in Q1 2025 compared to Q1 2024.
• General and administrative expenses increased by $2.4 million in Q1 2025 compared to Q1 2024.
• The company experienced a net loss of $13.1 million for the first quarter of 2025.

Risks

• The company is carefully evaluating the optimal timing for pursuing additional development activities beyond the LOTUS trial due to current market conditions.
• The company's future performance is subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and market conditions.
• The forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalos control), which could cause actual results to differ from the forward-looking statements.

Future Outlook

The company expects its current cash to fund operations into at least 2027 and is evaluating the timing of additional development activities to potentially extend the cash runway into 2028. Topline data from the Phase 2 LOTUS trial is expected in 2026.

Management Comments

• Dr. Garry Neil, Chief Executive Officer, stated that the company is on track to deliver topline data in 2026 for the LOTUS trial and looks forward to demonstrating AVTX-009's potential as a leading treatment in HS.
• Dr. Garry Neil, Chief Executive Officer, stated that the Company is carefully evaluating the optimal timing for pursuing additional development activities beyond the LOTUS trial, such as the initiation of a second indication, to preserve capital until markets stabilize.

Industry Context

Avalo Therapeutics is focused on the treatment of immune dysregulation, specifically targeting inflammatory diseases with AVTX-009. The company's focus on hidradenitis suppurativa, a chronic inflammatory skin condition with limited treatment options, positions it within a growing market for novel therapies targeting IL-1.

Comparison to Industry Standards

• Companies like Novartis (Cosentyx) and AbbVie (Humira) have established treatments for inflammatory conditions, but there remains a need for more targeted therapies with improved efficacy and safety profiles.
• Avalo's AVTX-009, targeting IL-1, aims to address this need in hidradenitis suppurativa, a market with significant unmet needs.
• The Phase 2 LOTUS trial's design, including subcutaneous bi-weekly and monthly dosing regimens, aligns with industry standards for evaluating new treatments in this space.
• The primary endpoint of HiSCR75 at Week 16 is a commonly used metric in HS clinical trials, allowing for comparison to other investigational and approved therapies.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and progress in the LOTUS trial provide updates on the company's performance and future prospects.
• Employees: Increased R&D and G&A expenses may impact staffing and resource allocation.
• Patients: Progress in the LOTUS trial offers potential for a new treatment option for hidradenitis suppurativa.

Next Steps

• Continue enrollment and execution of the Phase 2 LOTUS trial.
• Evaluate AVTX-009 for additional immune-mediated diseases and announce a second indication.
• Carefully evaluate the optimal timing for pursuing additional development activities beyond the LOTUS trial.

Key Dates

Keywords

AVTX-009, Hidradenitis Suppurativa, LOTUS Trial, Financial Results, Avalo Therapeutics, Biotechnology, Clinical Stage, Immune Dysregulation